Inquiry Basket
CAS No.:
Cat No.: BADC-01897
4.5 
BCN-endo-PEG7-maleimide is a bioorthogonal ADC linker featuring bicyclononyne and maleimide groups, supporting rapid, copper-free click chemistry for site-specific antibody conjugation.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
BCN-endo-PEG7-maleimide is a cutting-edge ADC linker intermediate tailored for precise antibody-drug conjugate (ADC) construction and advanced bioconjugation studies. This linker combines a bicyclononyne (BCN) moiety with a maleimide functional group and a PEG7 spacer, enabling dual conjugation strategies through thiol-maleimide chemistry and bioorthogonal click reactions. The PEG7 spacer enhances hydrophilicity, reduces steric hindrance, and improves solubility of ADC payloads. In ADC linker design, BCN-endo-PEG7-maleimide provides predictable, site-specific attachment to cysteine residues on antibodies while preserving antibody folding and function, facilitating efficient delivery of cytotoxic payloads to target tumor cells.
For payload conjugation, BCN-endo-PEG7-maleimide is compatible with a broad spectrum of ADC cytotoxins, including DNA-damaging agents and microtubule inhibitors. The maleimide group reacts selectively with thiol groups, enabling reproducible and stable conjugation under mild conditions, while the BCN moiety supports strain-promoted alkyne-azide cycloaddition (SPAAC) for modular payload installation. The flexible PEG7 spacer minimizes aggregation and improves pharmacokinetics, allowing researchers to construct homogeneous ADCs with optimal solubility and stability. This linker allows the creation of multifunctional ADCs with tailored payload orientations for enhanced therapeutic efficacy.
In application scenarios, BCN-endo-PEG7-maleimide is widely used in oncology-focused ADC research, protein bioconjugation studies, and advanced targeted drug delivery systems. Its unique combination of hydrophilic PEG7 spacer, reactive maleimide, and bioorthogonal BCN group ensures site-specific, efficient, and versatile conjugation while maintaining antibody integrity. Leveraging BCN-endo-PEG7-maleimide in ADC linker design enables the development of highly functional, customizable conjugates that meet the precise demands of modern targeted therapies.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01841 | BCN-endo-PEG7-NH2 | 2143968-34-5 | |
| BADC-01805 | BCN-endo-PEG2-maleimide | 2675364-08-4 |
What is BCN-endo-PEG7-maleimide used for in ADCs?
BCN-endo-PEG7-maleimide is a linker that combines a maleimide reactive group with a BCN moiety for strain-promoted click chemistry. It enables site-specific conjugation of thiol-containing payloads to antibodies with improved solubility and flexibility.
29/1/2022
Could you advise how the PEG7 spacer improves BCN-endo-PEG7-maleimide performance?
The PEG7 spacer increases linker hydrophilicity and reduces aggregation of ADCs. It provides flexibility between the antibody and payload, preserving antigen binding and improving pharmacokinetics.
7/11/2018
We would like to know what conjugation chemistry BCN-endo-PEG7-maleimide employs.
BCN-endo-PEG7-maleimide employs both maleimide-thiol conjugation and strain-promoted alkyne-azide cycloaddition (SPAAC). This dual reactivity allows versatile payload attachment strategies under mild conditions.
5/12/2022
Dear team, which payloads are suitable for BCN-endo-PEG7-maleimide?
It is suitable for thiol- or azide-functionalized payloads, including cytotoxic drugs and imaging agents. The linker ensures efficient and stable conjugation while maintaining antibody integrity.
29/8/2018
Good afternoon! Could you please advise on the recommended handling and storage precautions for BCN-endo-PEG7-maleimide?
BCN-endo-PEG7-maleimide should be stored at -20°C under desiccated conditions, protected from moisture and light. Avoid repeated freeze-thaw cycles. Aliquoting is advised to maintain maleimide functionality, ensuring consistent and efficient conjugation reactions in antibody-drug conjugate synthesis.
25/12/2022
— Dr. Robert Evans, Protein Chemist (USA)
BCN-endo-PEG7-maleimide linker provided excellent solubility and high reactivity, enhancing our ADC conjugation efficiency.
5/12/2022
— Prof. Elena Russo, Medicinal Chemist (Italy)
BOC Sciences supplied BCN-endo-PEG7-maleimide with consistent purity and superior batch-to-batch reproducibility.
25/12/2022
— Dr. Stefan Weber, Bioconjugation Specialist (Germany)
The linker’s long PEG chain minimized steric hindrance and improved payload accessibility.
29/8/2018
— Ms. Laura Smith, R&D Manager (UK)
Excellent technical support and documentation accompanied BCN-endo-PEG7-maleimide, facilitating smooth workflow.
29/1/2022
— Dr. Ingrid Jensen, ADC Project Lead (Denmark)
Using BCN-endo-PEG7-maleimide, we achieved reproducible ADC yields and minimal side reactions.
— Mr. Felix Martin, Senior Scientist (France)
The product’s solubility profile improved high-throughput conjugation efficiency. Highly satisfied.
7/11/2018
BCN-endo-PEG7-maleimide
Required fields are marked with *
BCN-endo-PEG7-maleimide
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
